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Abstract
Bile formation, the exocrine function of the liver, represents a process that is unique to the hepatocyte as a polarized
epithelial cell. The generation of bile flow is an osmotic process and largely depends on solute secretion by primary active
transporters in the apical membrane of the hepatocyte. In recent years an impressive progress has been made in the discovery
of these proteins, most of which belong to the family of ABC transporters. The number of identified ABC transporter genes
has been exponentially increasing and the mammalian subfamily now counts at least 52. This development has been of crucial
importance for the elucidation of the mechanism of bile formation, and it is therefore not surprising that the development in
this field has run in parallel with the discovery of the ABC genes. With the identification of these transporter genes, the
background of a number of inherited diseases, which are caused by mutations in these solute pumps, has now been
elucidated. We now know that at least six primary active transporters are involved in canalicular secretion of biliary
components (MDR1, MDR3, BSEP, MRP2, BCRP and FIC1). Four of these transporter genes are associated with inherited
diseases. In this minireview we will shortly describe our present understanding of bile formation and the associated inherited
defects. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Bile formation
1.1. Bile £ow
The small apical (canalicular) domains of hepato-
cytes are arranged into a luminal meshwork of tu-
bules between adjacent hepatocytes and these are the
sites of primary bile formation. From this canalicular
network bile £ows to the small ductules and subse-
quently to the larger ducts. Bile formation is an os-
motic process, which means that the generation of
water £ow is preceded by the active secretion of sol-
utes, followed by the osmotic attraction of water.
Solute secretion at the canalicular level is a process
that is mediated by primary active transporters (¢g.
1). Water £ow is generally thought to be mainly
through the tight junctions and not through special-
ized water channels (aquaporins) because these were
not found in hepatocytes [1,2]. More recently, how-
ever, it has become clear that a new water channel,
aquaporin 8, is expressed in hepatocytes [3]. This
channel is inserted into the hepatocyte plasma mem-
brane in a regulated fashion [4] and may therefore
contribute to the net e¥ux of water across the cell.
The main constituents of the primary biliary £uid are
bile salts; hence £ow mainly depends on the extent of
bile salt secretion. Indeed, classical experiments have
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demonstrated in several species [5,6] that there is a
more or less linear relationship between bile salt out-
put and bile £ow. Extrapolation of the £ow to very
low rates of bile salt secretion suggests that a so-
called bile salt-independent fraction of bile £ow
also exists and more recent studies indeed indicated
that canalicular glutathione secretion [7,8] and duct-
ular bicarbonate secretion [1] also contribute to over-
all hepatic bile £ow. The main determinant of overall
bile £ow is the volume of water generated at the
canalicular level. However, between species there is
considerable di¡erence in the extent to which the bile
duct epithelial cells contribute to the generation of
water [9]. The current model for the contribution of
ductular £ow, proposed by the group of LaRusso [1],
is that of a combined action of the chloride channel,
CFTR, and the chloride/bicarbonate exchanger, AE-
2, leading to net bicarbonate secretion which is fol-
lowed by water transport through aquaporin 1
(AQP1). Expression of all of these transporters has
been demonstrated in the apical domain of bile duct
epithelial cells [10^12].
1.2. Bile salt transport
First pass elimination of bile salts by the liver can
be up to 90% and is mediated primarily by the Na-
taurocholate cotransporting peptide, NTCP [13] (of-
¢cial gene code SLC10A1). Since this transport is
driven by the sodium gradient, it is capable of con-
centrating bile salts in the hepatocyte. This protein is
exclusively expressed in the liver and localized in the
basolateral membrane of the hepatocyte. Ntcp has
a⁄nity for both conjugated and unconjugated bile
salts [14^16]. Although the transporter also catalyzes
the uptake of estrone 3-sulfate [16], its substrate spe-
ci¢city seems to be largely con¢ned to bile salts.
Members of the family of OATPs, such as OATP2
(SLC21A6) and OATP-A (SLC21A3), are also capa-
ble of transporting bile salts but contribute less and
do not act in a concentrative fashion [17].
There has been a long-standing debate on the
mechanism of intracellular transport of bile salts
through the hepatocyte. It was thought for a long
time that this might involve vesicular transport, but
there is no de¢nitive proof for this and the current
paradigm is that bulk bile salt transport does not
require vesicular transport and only involves binding
to cytosolic bile salt binding proteins. The most im-
portant of these proteins is 3KOH-steroid dehydro-
genase which is present in extremely high concentra-
tion in the hepatocyte cytosol [18,19]. This binding
seems important not only in view of the detergent
properties of bile salts at higher concentrations but
also because of their potent ability to induce apopto-
sis in hepatocytes at low concentrations [20,21].
It was originally thought that canalicular bile salt
secretion was a process driven by the negative mem-
brane potential inside the hepatocyte [22,23]. After
the discovery of canalicular ATP-dependent process-
es for both amphipathic drugs [24] and organic
anions [25,26] it became clear that also bile salts
are transported in a primary active ATP-dependent
fashion [27,28] (Table 1). Bile salts are pumped
across the canalicular membrane via the bile salt ex-
port pump (BSEP, gene code ABCB11) (Fig. 1). The
gene encoding this transporter was initially partially
cloned from the pig and originally designated sister
of P-glycoprotein (Spgp) [29]. Subsequently the full
cDNA was isolated from rat [30], and murine liver
Table 1
Transporters involved in primary bile formation
Transporter trivial name(s) Gene code Substrate(s) Defective in
FIC1 ATP8B1 ? PFIC type 1
BSEP (sPgp) ABCB11 bile salts PFIC type 2
MDR3 Pgp (in mouse: Mdr2 Pgp) ABCB4 phosphatidylcholine PFIC type 3
MDR1 Pgp (in mouse: Mdr1a and 1b Pgp) ABCB1 amphipathic drugs (neutral and cationic) ?
MRP2 (cMOAT) ABCC2 amphipathic drugs (anionic and neutral) Dubin^Johnson syndrome
BCRP (MXR, ABCP) ABCG2 amphipathic drugs ?
ABCG5 ABCG5 (phytosterols) Sitosterolemia
ABCG8 ABCG8 no direct evidence yet
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[31^33]. Bsep is a genuine ABC transporter accord-
ing to the classical paradigm of 12 transmembrane
spanning domains and two nucleotide binding folds.
The gene product from di¡erent species behaves as a
140^160 kDa protein on SDS^PAGE. Gerlo¡ et al.
[30] demonstrated that plasma membrane vesicles
from Sf9 cells transfected with the rat Bsep cDNA
were capable of taking up taurocholate in an ATP-
dependent fashion with a Km of 5.3 WM. These
vesicles also transported the taurine conjugates of
chenodeoxycholate and ursodeoxycholate. No trans-
port could be observed of glycocholate and cholate
[30]. Murine Bsep was shown to transport taurocho-
late, taurochenodeoxycholate and glycocholate [33].
The transport properties of human BSEP have not
yet been reported on. Although initially Bsep expres-
sion was observed in the liver only, Lecureur et al.
[31] reported weak expression of Bsep in mouse brain
as determined by Western blotting. This may provide
an explanation for the reported observation of bile
salt transport across the blood^brain barrier [34].
After reaching the intestine, bile salts are e⁄ciently
resorbed in the terminal ileum in a sodium-depen-
dent mechanism by the apical bile salt transporter
(designated ASBT and formerly IBAT, o⁄cial gene
code: SLC10A2) [35^37]. When transfected in COS
cells, the human ASBT [37] recognizes both primary
and secondary bile salts in their unconjugated as well
as their taurine-conjugated form. Both the rabbit and
the human ileal transporters have a more narrow
substrate speci¢city than the hepatic sodium-depen-
dent transporter [37,38]. While the hepatic transport-
er also transports compounds like estrone 3-sulfate,
the ileal transporter seems to be more speci¢c for bile
salts.
Within the enterocyte bile salts are bound to the
ileal bile salt binding protein. It was demonstrated
recently that the expression of this protein is strongly
regulated by the prevailing bile salt concentrations,
suggesting that it may play a role in the regulation of
the enterohepatic cycle of bile salts. This regulation is
driven by the nuclear receptor pair FXR/RXR [39].
FXR recognizes dihydroxy bile salts like deoxycho-
late and chenodeoxycholate [40]. It is now becoming
clear that nuclear receptors regulate several steps in
bile salt metabolism and transport [41^47].
How bile salts leave the enterocyte at the basolat-
eral pole is currently unknown. MRP3 (o⁄cial gene
Fig. 1. Transporters involved in canalicular bile formation. In the left canalicular membrane the ABC transporters are indicated, of
which the function has been established. In the right canalicular membrane the heterodimer of ABCG5 and ABCG8 has been drawn,
but this is speculative because the presence of these two half-transporters in the canalicular membrane has not been demonstrated yet.
It has also not yet been proven that phytosterols are transported by this transporter pair. Also the P-type ATPase FIC1 is indicated;
the presence of this protein in the canalicular membrane has recently been proven [98], but its substrate is as yet still unknown.
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code ABCC3) is expressed in the basolateral mem-
brane of enterocytes and it has been shown that rat
Mrp3 transports taurocholate (with a Km of 16 WM
[48]) and human MRP3 transports glycocholate (Km
248 WM [49]). Whether MRP3 is the physiologically
relevant transporter for release of bile salts into the
blood remains to be determined. The bile salts are
carried by the mesenteric blood to the portal vein
and e⁄ciently withdrawn from the blood by the liver.
The above described mechanisms ensure that bile
salts undergo extensive enterohepatic circulation dur-
ing which only minor amounts (1^3% per cycle) are
lost. It must be stressed that this description of the
mechanism of enterohepatic bile salt cycling only
holds for the main bile salts, i.e. taurine- or gly-
cine-conjugated cholate and chenodeoxycholate.
Within the gut there are extensive deconjugation
and dehydroxylation, which give rise to many sec-
ondary bile salts and bile salt metabolites several of
which have cholestatic properties. Depending on the
species under study, these metabolites can be more or
less e⁄ciently rehydroxylated and conjugated to yield
less toxic bile salts. An important example of this is
lithocholate, the bacterial dehydroxylation product
of chenodeoxycholate. The exact mechanisms of en-
terohepatic cycling of such metabolites have not suf-
¢ciently been studied. This will nevertheless be very
important in the face of the potent cholestatic prop-
erties of some of these compounds.
1.3. Transport of lipids
The second most important class of biliary constit-
uents are the lipids. Biliary lipids mainly consist of
phospholipid (almost exclusively phosphatidylcho-
line) and cholesterol. The ratio in which these two
lipids are secreted varies considerably between spe-
cies. In rodents the phospholipid over cholesterol
ratio is 5^10 while in man this is considerably lower.
The relatively high concentration of cholesterol in
human bile represents the major risk factor to gall-
stone formation. Upon production of a knockout
mouse for the Mdr2 gene it was discovered that the
encoded transporter is essential for biliary lipid se-
cretion [50]. In the absence of Mdr2 Pgp, mice do not
secrete phospholipid nor cholesterol. In di¡erent ex-
perimental systems it was subsequently demonstrated
that the murine Mdr2 Pgp as well as the human
orthologue MDR3 Pgp are phosphatidylcholine
(PC) translocators [51^53].
On the basis of available data, we have proposed a
model [54] in which PC, after delivery to the inner
lea£et of the canalicular plasma membrane, is trans-
located to the outer lea£et and subsequently resides
in PC-rich lipid domains that are laterally separated
from the more rigid sphingolipid-rich lipids of the
outer canalicular membrane lea£et. This rigid lipid
layer is necessary to prevent solubilization of the
canalicular membrane by high bile salt concentra-
tions in the canaliculus. Interaction between sphingo-
myelin and cholesterol greatly enhances this rigidity
and increases resistance towards bile salts [55].
Sphingomyelin has high a⁄nity for cholesterol [56]
and these two lipids tend to segregate in lateral do-
mains [57,58]. The more £uid PC-rich microdomains
are destabilized by the canalicular bile salt molecules
and, in combination with the continuous pumping of
PC into these domains, vesiculation of PC-rich mem-
brane bilayer occurs. These vesicles then pinch o¡ to
give rise to typical biliary lipid vesicles [54]. In a
meticulous morphometric study at the electron mi-
croscopy (EM) level, Crawford et al. [59,60] have
provided morphological evidence for such a mecha-
nism.
The mechanism of cholesterol secretion into bile is
still largely unknown. As yet, no direct evidence ex-
ists for the involvement of a translocator protein
which, in analogy with Mdr2/MDR3 Pgp for phos-
pholipids, would catalyze the translocation of choles-
terol across the membrane. Controversy exists on the
rate of spontaneous £ip-£op of cholesterol across
biological membranes. Cholesterol is not secreted
into bile in the absence of phospholipid secretion;
this is caused by the fact that simple bile salt micelles
have very poor cholesterol solubilizing capacity, es-
pecially those of the more hydrophilic bile salt spe-
cies, such as muricholate (the main murine bile salt)
and ursodeoxycholate. This observation does, how-
ever, not exclude the possibility that cholesterol
translocation needs a transporter protein. Indeed, re-
cent evidence suggests that the two half-transporters
ABCG5 and ABCG8 are involved in the elimination
of plant sterols. Transport has thus far not been
demonstrated directly, but this function can be in-
ferred from accumulation of plant sterols in patients
with sitosterolemia, who have a mutation in either of
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the two genes encoding these proteins (see below).
ABCG5 and ABCG8 are expressed in the intestine
and the liver.
Recently, yet another ABC transporter, ABCA1,
has been implicated in the transport of cholesterol.
Several groups simultaneously discovered that
ABCA1 is the causative gene for Tangier disease
[61^64]. Tangier disease is a rare inherited disorder
characterized by the virtual absence of high density
lipoprotein (HDL). Fibroblasts from these patients
are incapable of donating cholesterol and phospho-
lipid to lipid-poor apolipoprotein (apo) A-I, a step
that is essential for maturation of the lipoprotein.
When the association between ABCA1 defects and
Tangier disease was discovered, the initial suggestion
was that ABCA1 transports cholesterol, but recent
evidence demonstrates that this is not the case [65].
Most likely ABCA1 functions primarily as an out-
ward phospholipid translocase rather than a choles-
terol transporter. Translocation of phospholipid to
lipid-poor apoA-I probably secondarily facilitates
the transfer of cholesterol. Recently, Vaisman et al.
[66] reported a study on transgenic mice that over-
express ABCA1. As expected, these mice had in-
creased plasma levels of HDL. The authors also re-
ported that the concentration of cholesterol in bile
was increased. This could mean that ABCA1 also
ful¢lls a function in lipid secretion in the canalicular
membrane. To investigate this aspect in a more rig-
orous model, Groen et al. [67] measured cholesterol
secretion rates into bile in Abca1 (3/3) mice during
bile diversion. They observed no di¡erence between
Abca1 (3/3) mice and controls. This rules out the
possibility that Abca1 contributes to biliary choles-
terol e¥ux, unless this function would be completely
taken over by another gene with compensatory ex-
pression, which is rather unlikely.
1.4. Transport of amphipaths
Thus far, three ABC transporters for amphipaths
have been localized to the canalicular membrane:
MDR1 P-glycoprotein (gene code ABCB1), MRP2
(gene ABCC2) and BCRP (gene code ABCG2). In
transfected cells and/or selected cell lines all three
transporters confer multidrug resistance against a
wide spectrum of cytotoxic agents. MDR1 P-glyco-
protein pumps many neutral and positively charged
organic compounds across the plasma membrane out
of the cell. In view of the diversity of transported
compounds, the de¢nition of its substrate speci¢city
has remained di⁄cult. Clearly, molecular weight,
bulkiness of the molecule and charge of the molecule
are important parameters [68]. The role of MDR1
Pgp in the protection against xenobiotics has been
¢rmly established by the generation of knockout
mice for both the Mdr1a and the Mdr1b gene (in
mice two Mdr1 genes ful¢ll the function of the single
MDR1 gene in man). This knockout animal is hyper-
sensitive for a number of toxic compounds and
important sites of expression are the blood^brain
barrier, the intestinal epithelium and the hepato-
canalicular membrane [69,70]. Thus far, no human
disorders are known that are associated with a de-
fect in the MDR1 gene. It is of interest to note, how-
ever, that Panwala et al. [71] detected a high inci-
dence of colitis in Mdr1a3/3 mice. This chronic
intestinal in£ammation could be prevented by treat-
ment with a mix of broad spectrum antibiotics,
suggesting that intestinal bacteria and/or their prod-
ucts play a role in this phenomenon. Polymorphisms
have been detected in the MDR1 gene [72,73] and
these may be associated with alterations in the oral
bioavailability of certain pharmaca [74]. The
polymorphism C3435T was found to be associated
with reduced MDR1 Pgp expression in the duode-
num and this correlated with increased oral bioavail-
ability of digoxin [72]. On the other hand no change
in the bioavailability of cyclosporin A was observed
[75].
MRP2 (formerly also called cMOAT for canalicu-
lar multispeci¢c organic anion transporter, gene code
ABCC2) was discovered as the liver speci¢c homo-
logue of another multidrug resistance transporter,
MRP1 [76,77]. The two transporters have, however,
opposite membrane localizations; MRP1 is expressed
in the basolateral membrane and MRP2 in the apical
membrane of epithelia. While MRP1 is expressed in
most cell types, MRP2 is only found in hepatocytes
and to a lesser extent in enterocytes and kidney prox-
imal tubule cells [78,79]. MRP1 and MRP2 have
highly similar substrate speci¢cities [78,79]. Both
transporters recognize a wide spectrum of organic
anions; this includes unconjugated anions but also
anionic conjugates of glucuronic acid, glutathione
and sulfate. More recently, it has become clear that
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these transporters can also pump uncharged com-
pounds. It appears that the transporters can accom-
modate uncharged amphipathic compounds together
with a glutathione molecule in a co-transport mech-
anism. Experiments with plasma membrane vesicles
containing MRP1 revealed that this transporter does
not pump vincristine to any signi¢cant extent. How-
ever, addition of GSH strongly stimulated the trans-
location of vincristine [80]. A similar involvement of
GSH was found for MRP2-mediated transport of the
uncharged carcinogen PhIP [81]. This mechanism
greatly enhances the versatility of these transporters.
In the intestine MRP2 may play a similar role as
MDR1 Pgp in the defence against toxic compounds
in the gut lumen [81].
Another member of this subfamily, MRP3, was
already mentioned above. This transporter is also
expressed in the basolateral membrane of cholangio-
cytes and portal hepatocytes. During cholestasis its
expression is highly induced in both cell types. It may
function as a rescue mechanism for the cholestatic
hepatocytes to prevent intracellular accumulation of
bile salts and organic anions (see below).
More recently, BCRP (breast cancer related pro-
tein, also termed MXR or ABCP, gene code ABCG2)
was identi¢ed as yet another ABC transporter that is
overexpressed in anthracycline-resistant cell lines
[82]. Upon cloning of its cDNA, it turned out to
be a half-transporter, i.e. a protein consisting of
only six transmembrane helices and one nucleotide
binding domain as opposed to the classical duplicate
motif. Other members of the ABCG subfamily (as
well as some members from other subfamilies) are
also half-transporters. Examples are ALDP (adeno-
leukodystrophy protein), which is localized in the
peroxisomal membrane and is thought to catalyze
the transport of activated long chain fatty acids,
and TAP1 and 2, which mediate peptide transport
across the endoplasmic reticulum membrane, neces-
sary for antigen presentation. In general, the half-
transporters are believed to dimerize, either as homo-
dimers or as heterodimers, into functional pumps.
Transfection of the ABCG2 cDNA in cells confers
resistance against mitoxantrone, topotecan, doxoru-
bicin, daunorubicin and rhodamine 123 [82]. Using
monoclonal antibodies against the ABCG2 gene
product, Maliepaard et al. [83] recently demonstrated
that this protein is present in the plasma membrane
of endothelial cells and in the apical membrane of
intestinal epithelial cells (both colon and small intes-
tine) and hepatocytes. The latter strongly suggests
that it is also involved in biliary secretion of amphi-
paths. Using a speci¢c inhibitor of BCRP,
GF120918, Jonker et al. [84] showed that this trans-
porter reduces the oral bioavailability of topotecan
and other BCRP substrates in the intestine by pump-
ing these compounds back into the lumen. Thus,
BCRP as well as MDR1 and MRP2 are important
in determining the oral bioavailability of drugs and
toxins.
2. Defects in canalicular transport
2.1. Progressive familial intrahepatic cholestasis
It has been known for a long time that a group of
pediatric patients exists, who su¡er from an inherited
form of progressive intrahepatic cholestasis. This
group has been described under various other syno-
nyms such as fatal familial intrahepatic cholestasis
[85], or progressive idiopathic cholestasis [86]. The
¢rst report identi¢ed this disease entity in an Amish
family (the Byler family), where seven members of
four related sibships su¡ered from the same symp-
toms [85]. These children presented with steatorrhea,
diarrhea, jaundice with intermittent exacerbations,
hepatosplenomegaly and failure to thrive. Because
of the patient family history it was clear that this
represented a recessively inherited disease which
was called Byler’s disease after the family. Subse-
quent studies showed that a similar disease pheno-
type also existed outside the Amish community [87^
89]. Patients with the same disease phenotype that
did not belong to the Byler pedigree were generally
described as su¡ering from Byler syndrome, due to
the uncertainty of the genetic cause of this form. The
outcome of the disease was generally fatal due to
liver failure within the ¢rst decade of life. The advent
of liver transplantation for children provided the op-
portunity to cure these patients. In further studies
biochemical and histological features provided sup-
port for heterogeneity of this disease entity, although
the clinical development was very similar. First and
foremost the group fell into two parts, one subgroup
of patients with a high serum Q-glutamyltranspepti-
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dase (GGT) activity and the other with a normal
serum GGT activity [90,91]. The latter form was
the most frequent and included the patient group
from the original Byler pedigree. Further analysis
learned that these subgroups di¡ered in more aspects
than only the serum GGT. Liver histology of pa-
tients with high GGT PFIC revealed prominent
bile duct proliferation and cirrhosis which were ab-
sent or much less prominent in patients with low
GGT. In the last few years considerable progress
was made in identifying the genetic background of
this group of patients, although it must be stressed
that not all involved genes have been identi¢ed yet.
There are at least three groups which are now com-
monly designated by PFIC type 1, type 2 and type 3.
Type 1 and type 2 patients have a low serum GGT
activity, while type 3 patients have a high serum
GGT activity.
2.2. Progressive familial intrahepatic cholestasis
type 1 (formerly called Byler’s disease)
Byler’s disease primarily manifests itself as a
chronic intrahepatic cholestasis. Bile salt concentra-
tions are high in serum and very low in bile, suggest-
ing that hepatic transport is impaired. The jaundice
in these patients is regarded as a secondary conse-
quence of insu⁄cient bile £ow, the latter being de-
pendent on bile salt secretion. This also holds for the
fat-soluble vitamin de¢ciency and steatorrhea which
are the consequence of impaired fat absorption, due
to the absence of bile salts from the intestine. Liver
transplantation is presently the main therapeutic op-
tion for this progressive disease that ends in liver
failure. It is of importance to note, however, that
interruption of the enterohepatic circulation (chronic
bile diversion) was reported to improve the clinical
picture of these patients dramatically. Whitington et
al. [92] described a procedure in which chronic exter-
nal partial bile diversion was achieved through a je-
junal stoma in four patients. In these patients pruri-
tus dramatically improved and serum bile salt levels
fell from s 200 WM to less than 10 WM. Several later
studies have reported similar results [93^95]. This did
not occur in all patients, however, and it would be of
great interest to distinguish the bene¢cial e¡ect of
this procedure in PFIC type 1 vs. type 2 patients
(see below).
With the patients from the Byler pedigree and
their family members a genetic screen was performed
to identify the disease locus [96]. This was located on
chromosome 18q21-q22, the same chromosomal re-
gion on which a very similar disease type, benign
recurrent intrahepatic cholestasis, was localized (see
below). A combined search for the two disease loci
led to the identi¢cation of the mutated gene, FIC1
(gene code ATP8B1), and its mutations in a group of
patients, including those from the original Byler ped-
igree [97]. More recently it became possible to stain
the protein by Western blotting and immunohisto-
chemistry [98]. It is a 140 kDa protein which is lo-
calized in the canalicular membrane of the hepato-
cyte as well as in the apical membrane of bile duct
epithelial cells. The protein was virtually absent from
a liver specimen of a patient with the common Amish
mutation. Many issues concerning this protein re-
main puzzling, however. Expression of FIC1 in liver
is actually quite low, while the gene is highly ex-
pressed in intestine and pancreas [97]. Expression is
also found in many other tissues. Thus, it is unclear
why the absence of FIC1 from many tissues leads
primarily to a phenotype in the liver. On the basis
of sequence homology this gene must be a member of
the P-type ATPase family. Within this family, sub-
groups of transporters with di¡erent functions have
been identi¢ed. The subgroup of cation pumps har-
bors the plasma membrane (Na+K)-ATPase and
the gastric (K+H)-ATPase. A second subgroup
contains metal ion transporters, such as the hepatic
copper transporter, mutated in Wilson’s disease [99],
and the extrahepatic copper transporter that is defec-
tive in Menke’s disease [100]. The function of FIC1
as a transporter is as yet unknown, but it has highest
homology with the drs2 protein from yeast and with
the bovine ATPase II (gene code ATP8A1), which
form the third subgroup of P-type ATPases [97,
101]. Evidence was presented that drs2 would be an
aminophospholipid £ippase, that translocates phos-
phatidylserine and phosphatidylethanolamine from
the outer lea£et to the inner lea£et of the cell mem-
brane [101]. This is a controversial issue, however,
because later publications showed that the protein
was unable to translocate lipids [102,103] and sug-
gested that it might be involved in metal ion trans-
port [104]. A mutant yeast strain has been produced
in which the drs2 gene is disrupted and this yeast
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strain has a defect in ribosome assembly as well as a
cold sensitive phenotype [105]. To our knowledge no
publications have reported on the function of either
the ATPase II or FIC1 by transfection of their
respective cDNAs in cells. Thus, it remains to be
demonstrated what the function of the two gene
products is. It also remains enigmatic how the ab-
sence of FIC1 can lead to defective canalicular bile
salt transport. Given the fact that BSEP is the main
canalicular bile salt transporter, that FIC1 is mainly
expressed in the intestine, and that chronic bile di-
version leads to disappearance or reduction of PFIC
type 1 symptoms, it can be speculated that FIC1
activity plays a role in the enterohepatic circulation
of bile salts and that the intrahepatic cholestasis in
these patients is a secondary consequence of dysre-
gulation of the enterohepatic circulation [106]. In the
line of this hypothesis several possible functions of
FIC1 can be envisioned. FIC1 may be an amino-
phospholipid £ippase, as originally suggested; the
(inward) £ipping of aminophospholipids could be
of importance for the regulation of the activity of
other transporters such as the bile salt transporters
in liver and intestine. It would have to be assumed
then that lipid asymmetry is of major regulatory
function for normal bile salt transport. Alternatively,
the inward £ipping of PS might be important for the
binding of auxiliary proteins to, or fusion of vesicles
with, the cytosolic lea£et of the plasma membrane of
hepatocytes and/or enterocytes. It is known that
binding of certain proteins (like annexin) as well as
fusion of exocytotic vesicles critically depend on the
PS concentration in the cytosolic membrane lea£et
[107]. Another possibility is that FIC1 is a bile salt
pump itself. FIC1 could have a⁄nity for hydropho-
bic bile salts and/or cholestatic bile salt metabolites.
The latter mostly concern metabolites from the pri-
mary bile salts, cholate and chenodeoxycholate, pro-
duced by bacteria in the gut. The high expression of
FIC1 in the gut might serve as a direct defense
against such compounds. In the absence of an out-
ward pump function of FIC1 for hydrophobic bile
salt (metabolites), these cholestatic agents might ac-
cumulate in plasma and induce cholestasis. This
function would also explain why chronic bile diver-
sion improves the disease phenotype. In line with this
hypothesis it has been observed that bile from PFIC
type 1 de¢cient patients contains very low amounts
of bile salts with a disproportionately low content of
the hydrophobic bile salts [88,108]. If this hypothesis
is right, FIC1 would represent a multidrug resistance-
like gene rather than a speci¢c lipid translocator. It
should be noted in this context that the homologous
Neo1 gene in yeast confers resistance against amino-
glycosides [109]. It is not clear, however, whether this
resistance is mediated at the level of transport.
2.3. Benign recurrent intrahepatic cholestasis (BRIC)
With the identi¢cation of the disease locus for
PFIC type 1 and the responsible gene, FIC1, it be-
came clear that the same gene is mutated in BRIC.
BRIC most likely represents a mild form of PFIC
type 1. PFIC type 1 may start with bouts of choles-
tasis and progressively develops into chronic persis-
tent cholestasis, but in BRIC patients the phenotype
remains restricted to periods of cholestasis that re-
solve after days to months. Importantly, when cho-
lestasis resolves it leaves no detectable liver damage.
The main features of BRIC are elevated serum bile
salt concentrations, jaundice and pruritus. The mild-
er phenotype of BRIC compared to PFIC type 1
seems to correlate with the mutations found in these
two patient groups [97]. DNA sequencing of the
FIC1 gene learned that deletions, frameshifts and
nonsense mutations appear to lead to the PFIC
type 1 phenotype, while in BRIC patients generally
missenses are found. This allows the hypothesis that
the FIC1 protein with BRIC mutations may have
residual activity, while the protein is absent or non-
functional in PFIC type 1 patients [97].
Pruritus is a very prominent feature of both PFIC
type 1 and BRIC. The pathophysiological mecha-
nism of cholestasis-associated pruritus is still un-
known. Indirect evidence exists for the association
of pruritus with high levels of opioids (enkephalins).
Indeed, experiments with cholestatic rats demon-
strated increased plasma enkephalin levels and treat-
ment of cholestatic pruritic patients with opioid an-
tagonists such as naltrexone has relieved itching in
many but not all cases [110]. On the other hand,
pruritus is thought to be associated with high serum
and tissue bile salt concentrations, but a quantitative
relation between peripheral bile salt levels and the
severity of pruritus has never been established
[111]. It is interesting to note, however, that rifampi-
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cin was shown to relieve cholestasis-associated pru-
ritus in several cases [112]. It was found recently that
rifampicin is a ligand for the nuclear receptor SXR/
PXR and ligand activation of this receptor induces
expression of the cytochrome P-450 isoforms that are
capable of detoxifying hydrophobic bile salts
[113,114].
2.4. Progressive familial intrahepatic cholestasis
type 2
The phenotype of this form of PFIC is very similar
to that of type 1. Also for this form of PFIC the only
therapy is liver transplantation, because it develops
into liver failure. It was demonstrated by Strautnieks
et al. [115] that the disease locus of this subgroup of
patients resides on chromosome 2q24. They subse-
quently found that these patients have mutations in
the BSEP gene, which is present in this region [116].
Actually, until the genetic elucidation of PFIC types
1 and 2, it was di⁄cult to distinguish these forms.
The clinical, biochemical and histological features
are virtually indistinguishable. However, PFIC type
2 patients do not seem to su¡er from watery diar-
rhea, an aspect that may further emphasize the role
of FIC1 in the intestine. Electron microscopic anal-
ysis of liver tissue from PFIC type 2 revealed amor-
phous material in the canalicular space, while liver
specimens from type 1 patients displayed coarsely
granular bile [117]. The basis of this observation is
unknown, but might provide a clue to the function of
the FIC1. The outcome of the EM analysis is quite
likely to be very much dependent on the processing
of the tissue, so that this feature cannot be used for
diagnostic purposes.
The fact that mutations in the BSEP gene lead to
a virtual absence of bile salts from bile has led to the
conclusion that BSEP is the main bile salt transport-
er in the canalicular membrane. This is supported by
studies in which rat and murine Bsep were trans-
fected in Sf9 cells and shown to transport several
bile salts [30,33]. Both nonsense, missense mutations
and deletions in the BSEP gene were found in some
patients with low GGT PFIC, and these are now
described as having type 2 PFIC [115]. Very impor-
tantly, further screening by Strautnieks et al. [118]
seems to indicate that still another subgroup of pa-
tients exists in whom the disease locus neither local-
izes to the FIC1 region nor to the BSEP region. This
would mean that yet another gene is involved in low
GGT PFIC.
Very recently, Wang et al. [119] reported on a
knockout mouse for the Bsep gene. This animal did
not quite have the same phenotype as PFIC type 2
patients. Bsep3/3 mice are cholestatic in the sense
that taurocholate accumulates in the liver and little
taurocholate is excreted into bile. However, in con-
trast to the patients, these mice excrete substantial
amounts of tauromuricholate into bile as well as a
hitherto unde¢ned tetrahydroxy bile salt. Apparent-
ly, Bsep is not the only bile salt transporting system
in the canalicular membrane and another system is
capable of excreting tauromuricholate and the tetra-
hydroxy bile salt. This escape route prevents severe
and progressive cholestasis in these mice and as a
consequence these animals have hardly any histopa-
thological signs of liver injury. Because humans are
not capable of converting bile salts into muricholate
or tetrahydroxy bile salts to any signi¢cant extent,
this escape route is not present in man. Interestingly,
Bsep3/3 mice were found to have an increased
phospholipid and cholesterol secretion rate into
bile. The reason for this is unclear, but the accumu-
lation of taurocholate in the plasma might lead to an
induction of Mdr2 expression which will cause an
increased phospholipid and cholesterol secretion, be-
cause Mdr2 Pgp activity is the rate controlling step
in biliary lipid secretion [120,121]. It was shown in
rats that enlarging the bile salt pool increases the
expression of Mdr2 and phospholipid secretion into
bile [120].
2.5. Progressive familial intrahepatic cholestasis
type 3
As mentioned above, this form of PFIC is funda-
mentally di¡erent from types 1 and 2 in that these
patients have a high serum GGT activity. The onset
of this disease is somewhat later than in the other
two forms, but the histological picture is more se-
vere; there is strong bile duct proliferation and cir-
rhosis. The most prominent features of the disease
are portal hypertension, hepatosplenomegaly, jaun-
dice and pruritus. If untreated the disease develops
into liver failure. The genetic background of this
subgroup of PFIC patients was elucidated after it
BBADIS 62086 10-4-02
R. Oude Elferink, A.K. Groen / Biochimica et Biophysica Acta 1586 (2002) 129^145 137
was found that mice with a disruption in the Mdr2
gene, the murine orthologue of MDR3, develop a
similar phenotype (see below). This led Deleuze et
al. [122] to investigate the possible involvement of
this gene in PFIC. Subsequently, in a group of 31
patients with high GGT PFIC, 17 were found to
have a mutation in the MDR3 gene [123,124]. Since
the gene was not completely sequenced in all these
patients it is not clear whether the remaining 14 pa-
tients have as yet unidenti¢ed mutations or that an-
other gene might be involved in this form of PFIC.
MDR3 P-glycoprotein functions in the translocation
of phosphatidylcholine, thereby facilitating the secre-
tion of this phospholipid into bile. The secretion of
phospholipid is of crucial importance in the protec-
tion of the cellular membranes of the biliary tree
against the high concentrations of bile salt detergents
[54].
Treatment of patients with ursodeoxycholate
(UDCA) appeared to be bene¢cial in about half of
the cases [123]. Given the fact that the hepatic dam-
age is caused by bile salts, this is a rational treat-
ment, because UDCA is a hydrophilic bile salt that
has low cytotoxicity. Indeed, in Mdr23/3 mice with
the equivalent defect, feeding of this bile salt also
halted the disease process [125,126]. The observation
that not all patients improve on UDCA treatment
may be explained by the fact that administration of
this bile salt insu⁄ciently replaces the endogenous
bile salt pool. Thus, in patients who have no
MDR3 Pgp activity at all, the reduction of bile salt
cytotoxicity by UDCA is insu⁄cient, while in pa-
tients with residual phospholipid secretion, UDCA
might bring the overall bile salt cytotoxicity below
a critical threshold. Indeed, none of the patients with
a truncated MDR3 gene improved on UDCA, while
some of those with missense mutations did [123].
Interestingly, it became clear more recently that
defects in the MDR3 gene do not only give rise to
pediatric liver disease. Jacquemin et al. reported [127]
that the mother of a patient with PFIC type 3 and
several other women from this family su¡ered from
intrahepatic cholestasis of pregnancy. These women
turned out to be heterozygotes for the mutation in
the MDR3 gene, that caused PFIC type 3 in the
homozygous index patient. Moreover, Rosmorduc
et al. [128] reported on six gallstone patients, in
whom mutations in the MDR3 gene were found.
This included homozygous and heterozygous mis-
sense mutations as well as a heterozygous 1 bp in-
sertion leading to frameshift and truncation. None of
these mutations were observed in s 100 chromo-
somes from control subjects, suggesting that they
may be associated with the disease phenotype. These
two publications suggest that, apart from the severe
phenotype associated with complete or nearly com-
plete absence of MDR3 function, also milder pheno-
types exist that are associated with reduction but not
complete absence of MDR3 Pgp function.
2.6. Serum cholesterol level in PFIC patients
In several studies on patients with low GGT PFIC,
it was observed that these patients have a normal
plasma cholesterol level as opposed to other pediatric
and adult forms of cholestasis [85,129,130]. Very re-
cently, this was also reported for PFIC type 3 pa-
tients [123]. The plasma lipoprotein pro¢le of choles-
tatic patients reveals an abnormal lipoprotein
fraction in the low density lipoprotein (LDL) region.
This abnormal ‘cholestatic’ lipoprotein was charac-
terized as a unilamellar vesicle with an aqueous lu-
men, and was designated lipoprotein X (LpX) [131].
Using Mdr23/3 mice it could be shown that the
formation of LpX depends on the function of the
canalicular secretion machinery [132]. Wild type
mice develop hypercholesterolemia upon bile duct
ligation and this is associated with the presence of
massive amounts of LpX in the plasma, but LpX was
completely absent in plasma of Mdr23/3 mice [132].
Apparently, during cholestasis the formation of bili-
ary vesicles continues and the release of these vesicles
is redirected to the plasma compartment. Indeed, it
was shown that during bile duct ligation, the expres-
sion of Bsep as well as Mdr2 are not down-regulated
and that the proteins are redistributed from the ca-
nalicular membrane into an intracellular, subapical
compartment, where they may continue to function
in the formation of biliary vesicles. The conclusion
from these data is that during obstructive cholestasis
the continued formation of lipid vesicles by Mdr2/
MDR3 Pgp and the release into plasma lead to a
dysregulation of cholesterol homeostasis. In patients
with all forms of PFIC the process of biliary lipid
vesicle formation is impaired, because both bile salt
transport and phospholipid translocation are neces-
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sary for this process. The absence of either of these
two processes precludes the formation of biliary
vesicles and therefore during cholestasis also no
LpX will be formed. Thus the normal serum choles-
terol level represents an important diagnostic tool to
distinguish all forms of PFIC from other inherited or
acquired cholestatic syndromes.
2.7. Sitosterolemia
Sitosterolemia is a very rare, recessively inherited,
disease. The clinical presentation includes tendon
xanthomas, accelerated atherosclerosis particularly
a¡ecting males at a young age, hemolytic episodes,
and arthritis and arthralgias [133]. The hallmark bio-
chemical feature of the disease is the elevated con-
centration of plant sterols in plasma. Because sitos-
terol (24-ethyl cholesterol) is the most important
accumulated sterol in plasma of these patients (as
well as the most abundant plant sterol in the diet),
this disease is referred to as sitosterolemia. A host of
other sterol variants, such as campesterol, stigmaster-
ol and brassicasterol, are present in plants and other
components of the diet like shell¢sh. Several studies
have indicated that absorption of plant sterols in the
intestine is strongly increased in sitosterolemic pa-
tients. Control subjects absorb about 50^70% of diet-
ary cholesterol, but only less than 5% of the ingested
plant sterols. In stark contrast, sitosterolemic pa-
tients absorb plant sterols to about the same extent
(30^60%) as cholesterol. As a consequence there is
marked accumulation of these sterols in plasma and
this leads to similar accumulation in tissues like liver,
lung heart and red blood cells. The brain content of
plant sterols is low, indicating that the blood^brain
barrier is intact with respect to these exogenous ster-
ols [133]. Importantly, in normal subjects the low
amounts of absorbed sitosterol are quickly secreted
into bile so that only trace amounts of it can be
found in blood [133]. However, in sitosterolemic pa-
tients the biliary secretion of sitosterol and other
phytosterols is impaired [134^136]. Bile and plasma
analysis in two patients revealed a more than 30-fold
reduced bile/plasma ratio of total plant sterols com-
pared to controls [136]. These data show that phy-
tosterol handling in these patients is impaired at two
levels: absorption in the intestine and secretion into
bile.
The disease locus had been localized to chromo-
some 2p21 [137] and more recently ABCG5 and
ABCG8, the genes involved in this disease, were iden-
ti¢ed [138,139]. These encode two ABC half-trans-
porters from the G-subfamily. Separated by only
374 bp they are located in opposite orientation on
chromosome 2p21. Lee et al. [139] reported muta-
tions in the ABCG5 gene in nine patients, while
Berge et al. [138] identi¢ed mutations in the
ABCG8 gene of eight patients and in the ABCG5
gene of one patient. Both genes are expressed mainly
in liver and intestine [138,139].
As described above, ABC half-transporters are
thought to dimerize into functional pumps. The
fact that mutations in either ABCG5 or ABCG8
cause sitosterolemia suggests that these two half-
transporters indeed form a functional (and obliga-
tory) heterodimer. No studies have been reported
yet in which the cDNAs have been transfected in
cell lines in order to perform transport studies, nor
has the localization of the proteins in normal human
tissues been described yet. However, on basis of the
description of the increased sterol absorption and the
decreased biliary secretion in patients with sitostero-
lemia, it is tempting to speculate on the localization
and function of a potential heterodimer of ABCG5
and ABCG8. The minimum hypothesis would be
that this represents an outward pump for plant ster-
ols present in the apical membrane, which in the
intestine reduces absorption and in the liver mediates
canalicular secretion of these unwanted sterols.
2.8. The Dubin^Johnson syndrome
The Dubin^Johnson syndrome is a rare and be-
nign disorder which ¢rst has been described in 1954
[140]. The syndrome is characterized by a chronic,
predominantly conjugated, non-hemolytic hyperbilir-
ubinemia, caused by an impaired hepatobiliary trans-
port system for non-bile salt organic anions in the
canalicular membrane of the hepatocyte. Further-
more, liver histology is normal except for the, syn-
drome-characteristic, lysosomal accumulation of a
black pigment. This pigment was thought to be mel-
anin-like material but this remains controversial
[141]. Studies in the Mrp2-de¢cient GY/TR3 rat,
the animal model for this disease [76], suggest that
it is derived from accumulated, polymerized metab-
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olites of aromatic amino acids [142]. In addition, the
urinary coproporphyrin excretion in these patients is
abnormal [143]. Serum levels of endogenous bile salt
are normal and the hepatobiliary transport of bile
salts in these patients is una¡ected [78,144]. Cloning
of MRP2 [145] provided the opportunity to elucidate
the genetic background of this inherited disease. Sev-
eral mutations have now been reported and these
include missense, nonsense mutations, premature
stops, deletions etc. (for a review see [79]). The Du-
bin^Johnson syndrome is generally regarded as a be-
nign syndrome of which the hyperbilirubinemia is the
only problem. In the literature anecdotal reports ex-
ist on the occurrence of primary hepatocellular car-
cinoma [146^149]. Since the disease is very rare it is
impossible to assess whether the occurrence of HCC
is signi¢cant or not.
The animal models for the human Dubin^Johnson
syndrome are the GY/TR3 and the EHBR rat; two
naturally occurring mutants from the Wistar and
Sprague^Dawley colonies, respectively. The muta-
tions in the Mrp2 gene of both animal models have
been identi¢ed. The mutation in the TR3 rat is a
single nucleotide deletion which leads to a frameshift
and stop codon. A very low mRNA level and no
Mrp2 protein are detected in this animal [76]. In
the EHBR rat a one-nucleotide substitution results
in the introduction of a stop codon [150]. It is inter-
esting to note that both in the Dubin^Johnson syn-
drome and in the GY/TR3 rat the hyperbilirubine-
mia causes a dramatic induction of MRP3
expression. Also under conditions of obstructive cho-
lestasis Mrp3 was found to be strongly induced [151^
154]. MRP3 was recently cloned and identi¢ed as yet
another organic anion transporter [49,151,155^158].
Like MRP1 and in contrast to MRP2, MRP3 is lo-
calized in the basolateral membrane of epithelial cells
including hepatocytes [157,159]. Thus, increased
MRP3 expression may represent an escape route
for the excretion of accumulated organic anions
that are normally excreted into bile, but in the ab-
sence of MRP2 cannot leave the hepatocyte.
2.9. Cholestasis of pregnancy
Intrahepatic cholestasis of pregnancy (ICP) is a
reversible form of cholestasis that may develop in
the third trimester of pregnancy and usually rapidly
resolves after delivery. The incidence of ICP lies be-
tween 10 and 100 cases per 10 000 pregnancies, but
there is a strong ethnical background to this phe-
nomenon. Notably, in the Chilean population ICP
develops in as much as 16% of pregnancies and with-
in the Araucanian Indian subpopulation it is even as
high as 28% [160]. The main symptoms are pruritus
and, to a lesser extent, jaundice. Serum bile salt levels
are increased [161^163]. Increased incidence of fetal
distress, premature birth and even stillbirth in asso-
ciation with ICP has been reported (for a review see
[164]).
The reason for discussing ICP in this review is the
fact that genetic factors appear to be involved in the
development of this syndrome. As mentioned above,
ethnicity plays a role, but more recently it was also
found that heterozygosity for mutations in the
MDR3 gene predispose for ICP. Jacquemin et al.
[127] reported on the coexistence of PFIC type 3
and ICP in a consanguineous family. In this family,
six women had at least one episode of ICP and of
these six four were heterozygous for the mutation in
the MDR3 gene. DNA of the other two was not
analyzed. These data suggest that a reduced MDR3
Pgp activity predisposes for the development of ICP.
A predisposition for ICP is not only observed with
MDR3 mutations; already in the original description
of the Byler syndrome by Clayton et al. [85] it was
noted that the mother of a patient with this inherited
disease (now characterized as a defect in the FIC1
gene, see above) su¡ered from ICP. This has subse-
quently been con¢rmed in later studies [165,166].
Pregnancy may also unmask hitherto undiagnosed
Dubin^Johnson syndrome [167^169]. All in all, these
data suggest that during pregnancy there is a more or
less generalized reduction in bile formation and,
combined with a preexisting subclinical defect in
any of these transport systems, this may induce clin-
ical symptoms of cholestasis. The mechanism of re-
duced bile formation during pregnancy is unknown
but the prevailing hypothesis is that it is related to
the high levels of circulating hormones during the
last trimester. The most important observation in
support of this hypothesis is that the use of oral
contraceptives may also induce intrahepatic cholesta-
sis. Indeed, women with a history of ICP are also
prone to cholestasis induced by oral contraceptives
and vice versa [170]. Which hormones or hormonal
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metabolites are responsible is also unclear. In vivo
experiments in rats suggest that conjugated estrogen
metabolites can be cholestatic, but progesterones
may also play a role since these are produced at
high rates during the last phase of pregnancy [164].
These hormones may have an inhibitory e¡ect on
canalicular transporters, but since several transport
processes are a¡ected, it is also possible that the
membrane composition is changed or that there is
a generalized reduction in expression of transporters
or an increased degradation.
Note added in proof:
After completion of this manuscript a report by
the group of Arias has been published providing
data to suggest that FIC1 is a phospholid transloca-
tor that is capable of translocating phosphatidylser-
ine (PS). P. Ujhazy, D. Ortiz, S. Misra, S. Li, J.
Moseley, H. Jones, IM. Arias, Familial intrahepatic
cholestasis 1: studies of localization and function.
Hepatology 34 (2001) 768^775.
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